Literature DB >> 1715364

Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules.

I Stefanová1, V Horejsí.   

Abstract

mAb against human glycosyl-phosphatidylinositol-linked leucocyte surface Ag CD59 and CD55 immunoprecipitated from detergent lysates of HPB ALL cell line in addition to the respective Ag a common 80-kDa glycoprotein component and (glyco)lipids. The 80-kDa glycoprotein is different from otherwise similar CD44 Ag. The CD59 immunoprecipitate contained also a small amount of the CD55 glycoprotein and the CD55 immunoprecipitate minute amount of the CD59 Ag. These results are interpreted in terms of existence of noncovalent complexes resistant to dissociation by mild detergents and consisting of the 80-kDa glycoprotein, CD59 and CD55 glycoproteins, relatively tightly bound (glyco)lipids and possibly other so far unidentified components. These complexes contain probably also other glycosyl-phosphatidylinositol-linked Ag, as an anti-CD48 mAb immunoprecipitated also an apparently very similar complex. The complexes immunoprecipitated by mAb against the CD55, CD59, and CD48 Ag also contain a protein kinase activity. This type of complexes could not be demonstrated in several other cell types such as RBC, PBMC, and HeLa cells. However, a qualitatively very similar set of components was immunoprecipitated from the murine thymoma EL-4 cell line by an anti-Thy-1 mAb.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1715364

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Association between GM3 and CD4-Ick complex in human peripheral blood lymphocytes.

Authors:  M Sorice; T Garofalo; R Misasi; A Longo; J Mikulak; V Dolo; G M Pontieri; A Pavan
Journal:  Glycoconj J       Date:  2000 Mar-Apr       Impact factor: 2.916

2.  Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner.

Authors:  M Paula Longhi; Baalasubramanian Sivasankar; Nader Omidvar; B Paul Morgan; Awen Gallimore
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 3.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

4.  Piracy of decay-accelerating factor (CD55) signal transduction by the diffusely adhering strain Escherichia coli C1845 promotes cytoskeletal F-actin rearrangements in cultured human intestinal INT407 cells.

Authors:  I Peiffer; A L Servin; M F Bernet-Camard
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

5.  The sheep analogue of human CD59: purification and characterization of its complement inhibitory activity.

Authors:  C W van den Berg; R A Harrison; B P Morgan
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

6.  Binding of lipopolysaccharide (LPS) to an 80-kilodalton membrane protein of human cells is mediated by soluble CD14 and LPS-binding protein.

Authors:  J Schletter; H Brade; L Brade; C Krüger; H Loppnow; S Kusumoto; E T Rietschel; H D Flad; A J Ulmer
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

7.  An alternative way of CD4 and CD8 association with protein kinases of the Src family.

Authors:  T Cinek; I Hilgert; V Horejsí
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

8.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

9.  Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector.

Authors:  A Davies; B P Morgan
Journal:  Biochem J       Date:  1993-11-01       Impact factor: 3.857

10.  Heterotrimeric G proteins physically associated with the lipopolysaccharide receptor CD14 modulate both in vivo and in vitro responses to lipopolysaccharide.

Authors:  K R Solomon; E A Kurt-Jones; R A Saladino; A M Stack; I F Dunn; M Ferretti; D Golenbock; G R Fleisher; R W Finberg
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.